You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

CARDIOVASCULAR DISEASES UNDER THE ACTION OF OCCUPATIONAL FACTORS

2(22) 2010

https://doi.org/10.33573/ujoh2010.02.071

Basanets A. V., Andruschenko T. A.

CARDIOVASCULAR DISEASES UNDER THE ACTION OF OCCUPATIONAL FACTORS

SI «Institute for occupational health of AMS of Ukraine», Kyiv

Full article (PDF), UKR

The problem of cardiovascular diseases of different contingents of the working population is discussed in the article. Occupational factors of the modern production, which can occur as etiological agents of CVD, pathogenesis, peculiarities of clinical picture and the course of cardiovascular diseases under the influence of the working environment have been defined. Actual problems, concerning developing preventive measures for cardiovascular disease and their complications, which can result in disability and reduction of life duration of the working population have been elucidated.

Key words: cardiovascular diseases, professional factors, pathogenesis, clinical picture, prevention

References

  1. Kundiev Yu. I., Nahorna A.M. (2007), Profesiynezdorov'ya v Ukrayini, epidemiolohichnyyanaliz [Occupational health in Ukraine. Epidemiologicalanalysis], Avicenna, Kiev, Ukraine.
  2. Kannel W. B. Epidemiology and prevention of cardiac failure: Framingham Study insights / W. B. Kannel / / Europ. Heart J.- 1987.- V. 8, Suppl. F.- P. 23-26. https://doi.org/10.1093/eurheartj/8.suppl_F.23
  3. Baranov V. S. Genypredraspolozhennostiigeneticheskiypasport / V. S. Baranov, M. V. Aseyev, V. Ye. Baranova // Priroda.- 1999.- No 3.- S. 13-17.
  4. Raptovasmert, reanimatsiyaiintensyvnaterapiya / Volnyy I. F., Pasternak.H. I., Pyeshkov YU. V., Tkacheva M. YU. // Ekstrenamedychnadopomohana do hospitalʹnomuetapi.-Luhansk.- 2006.- S. 29-34.
  5. Voronkov L. H. Khronichnasertsevanedostatnist: Praktychnyyposibnyk / L. H. Voronkov.- K.: Chetvertakhvylya, 2004.- 198 s.
  6. Mazur N. A. Rekomendatsiyiporaptoviysmerti / RosiyskyyKonhreskardiolohiv. Dopovid (prezentatsiyanatsionalnykhrekomendatsiy VNOK) / N. A. Mazur.- Moskva, 2003.- S. 190.
  7. Kompleksnaprofilaktykaraptovoyismerti, infarktumiokarda, mozkovohoinsultu ta yikhnaslidkiv u hirnykivvuhilnykhshakht, metodychnirekomendatsiyi / [Valutsyna V. M., Cherkesov V. V., Perederiy H. S. ta in.].- Kyiv, 2008.- S. 31.
  8. Okorokov A. N. Raptovasertsevasmert (pervynnazupynkasertsya) / A. N. Okorokov // Diahnostykakhvorobvnutrishnikhorhaniv. Diahnostykakhvorobsertsyaisudyn.- Moskva: Medychnaliteratura.- 2002.- T. 6.- S. 414-423.
  9. Kryvohlaz B. A. Zakhvoryuvannyasertsevo-sudynnoyisystemy, yikhprofilaktykailikuvannya (v dopomohulektoram) / B. A. Kryvohlaz.-Kyiv, 1957.- S. 22.
  10. Hirnychyy Zakon Ukrayiny (st. 40) // Postanova Kabinetu Ministriv vid 18 lyutoho 2004 r. No 186 "ProvnesennyazminpoProhramipidvyshchennyabezpekypratsinavuhilnykhshakhtakh" (p. 99).
  11. Korzh YE. V. Patolohiyalehenisertsya u shakhtariv: Monohrafiya / Ye. V. Korzh, V. V., Mukhin.-Donetsk: Kashtan, 2004.- S. 164.
  12. Kobets H P. Ishemichnakhvorobasertsya u hirnychykhpratsivnykiv / H. P. Kobets, V. V. Cherkesov, R. A. Kopytina.-Kyiv: Zdorov'ya.- 1995.- S. 161.
  13. Trakhtenberg I.M., Babayan A.S., Kandaryan K.A. (1992), Khimichnifaktoryvyrobnychohoseredovyshchaisertsevo-sudynnasystema [Chemical factors of the work environment and cardio-vascular system], Aiastan, Yerevan, Armenia.
  14. Otsinka ta modyfikatsiyaryzykusertsevo-sudynnykhuskladnen u khvorykh z arterialnoyuhipertenziyeyu (metodychnirekomendatsiyi) / [Zharinov O. Y., Bobrova O. V., Vyeryezhnikova H. P. ta in.].- Kyiv.- 2009.- S. 18.
  15. Dzyak G. V. Sutochnoyemonitorirovaniyearterial'nogodavleniya / G V. Dzyak, T. V. Kolesnik, YU. N. Pogoretskiy.- Dnepropetrovsk, 2005.- S. 200.
  16. RekomendatsiyiUkrayinskohotovarystvakardiolohiv z profilaktykytalikuvannyaarterialnoyihipertenziyi.- K., 2008.- S. 76.
  17. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and of the European society of Cardiology. 2007 Guidelines for the management of arterial hypertension // Europ. Heart J.- 2007.- V.28.- P. 1462-1536.
  18. Chobanian A.V., Bakris G.L., Black H.R., et al., and the National High Blood Pressure Education Program Coordinating Committee, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The JNC 7 report // JAMA.- 2003.- V. 289.- P. 3560 -3572. https://doi.org/10.1001/jama.289.19.2560
  19. Boytsov S. A. Desyat' let poiskageneticheskoyosnovygipertonicheskoybolezni: trudnostiiperspektivy / S. A. Boytsov // Genetika.- 2002.- T. 8, No 5.- S. 56-64
  20. Kliniko-geneticheskiyeaspektygipotenzivnogootveta i obratnogorazvitiyagipertrofiilevogozheludochka u bol'nykharterial'noygipertoniyey / [Moiseyev V. S., KotovskayaYu. V., Kobalava ZH. D. i dr.] // Terapevticheskiyarkhiv.- 2002.- No 10.- C. 30-37.
  21. Geneticheskiyemarkerygipertrofiimiokardalevogozheludochka / [Karpov R. S., Puzyrev K. V., Stepanov V. A. i dr.] // Arterial'nayagipertenziya.-1999.- T 5.- S. 54.
  22. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow mediated vasodilatation in patients with coronary disease (BANF Study) / [Anderson T. J., Elstein E., Haber H. et al.].- J Am CollCardiol. 2000.- No 35.- P 60-66. https://doi.org/10.1016/S0735-1097(99)00537-9
  23. Konchalovskaya N. M. Serdechno-sosudistayasistemaprideystviiprofessional'nykhfaktorov / N. M. Konchalovskaya.-M.: Meditsina, 1976-S. 256.
  24. K otsenkeroliproizvodstvennykhfaktorovglubokikhugol'nykhshakht v razvitiiishemicheskoybolezniserdtsa u gornorabochikh / [Kobets' G P., Cherkesov V. V., Kopytina R. A. i dr.] // Gigiyenatruda i profpatologiya.- M, 1992.- S. 7-9.
  25. Kholopkina N.A., Gorblyanskiy YU. YU. Monitoring faktorovriskavozniknoveniyaserdechno-sosudistykhzabolevaniy u shakhtorov, stradayushchikharterial'noygipertoniyey / N. A. Kholopkina, YU. YU. Gorblyanskiy // Gigiyenatruda i profpatologiya.- M., 2003.- S. 59-61.
  26. Drobyshev V. V., Yefremov A. V., Loseva M. I. i dr. // Terapevticheskiyarkhiv.-2002.- No 10.- S. 62-65. https://doi.org/10.1055/s-2002-19513
  27. Profilaktika, diagnostika i lecheniyepervichnoyarterial'noygipertenzii v RossiyskoyFederatsii: PervyydokladNauchnogoobshchestvapoizucheniyuarterial'noygipertoniiVserossiyskogonauchnogoobshchestvakardiologov i Mezhvedomstvennogosonetaposerdechno-sosudistymzabolevaniyam (DAG Í) // Kardiologiya.- 2000.- No 11.- S. 65-93.
  28. Organov R. G // Vrach.- 2001.- No 7.- S. 3-6.
  29. Kobalava ZH. D., Kotovskaya YU. V. // Arterial'nayagipertoniya v voprosakhiotvetakh.-M., 2002.- S. 35-37.
  30. Epidemiologiyasvyazannykh s rabotoybolezney i neschastnykhsluchav // Dokladob"yedinennogokomiteta MOT VOZ poprof. gigiyene. Seriyatekhn. doklad., 10-y.- Zheneva, 1991.
  31. RekomendatsiyiYevropeyskohotovarystva z hipertenziyitaYevropeyskohokardiolohichnohotovarystva z likuvannyaarterialnoyihipertenziyi // JournalofHyper- tention.- 2003.- V. 21.- P. 1011-1053.
  32. Novyyerekomendatsiipodiagnostikeilecheniyuarterial'noygipertenziidlyaYevropyiSevernoyAmeriki (kommentariy) / Yu. N. Sirenko (2007) // Medicine Review.-2008.- No 2 (02).- C. 8-11.
  33. Birkenhager-Essential hypertension / Jan A. Staessen, Jiguang Wang, Giuseppe Bianchi, Willem H // LANCET, 2003.-V. 361.- P 1629-41. https://doi.org/10.1016/S0140-6736(03)13302-8
  34. Novyyepredstavleniya o patogenezekhronicheskoyserouglerodnoyintoksikatsii / KundievYu. I., Popov T.A., KrasnyukYe.P., Lukhtay V.A. // Vrachebnoyedelo.- 1978.- S. 7, 9-11.
  35. Vorob'yev Ye. I. Radiatsionnayakardiologiya / Ye. I. Vorob'yev.-M.: Atomizdat, 1971.
  36. Uroven' endoteliyzavisimoyvazodilatatsii i aktivnost' angiotenzinprevrashchayushchegofermentakakkriteriyterapiibol'nykh s myagkoy i umerennoyarterial'noygipertoniyey / [Yakimenko O. N., Gomazkov O. A., Ektova T. V. i dr.] // Kardiologiya.- 2005.- No 2.- S. 15-19.
  37. Moiseyev V. S. Arterial'nayagipertoniya u litsstarshikhvozrastnykhgrupp / V. S. Moiseyev, ZH. D. Kobalava.-Moskva: Meditsinskoyeinformatsionnoyeagentstvo, 2002.- S. 80-95.
  38. Vorob'yevYe. I. Sostoyaniyekletokmiokardakrolikovposlelokal'nogooblucheniyaoblastiserdtsa / Vorob'yevYe. I., Stepanov R P. // Radiobiologiya.- 1973.- No 6.- S. 844-849.
  39. Evans W. E. Pharmacogenomics-Drug Disposition, Drug Targets, and Side Effects / Evans W. E., McLeod H. L. // N.Engl.J. Med.- 2003.- V. 348, No 6.- P 538-546. https://doi.org/10.1056/NEJMra020526
  40. Maternal cigarette smoking, metabolic gene polymorphism, and infant birth weight / [Wang X., Zuckerman B., Pearson C. at al.] // J.A.M.A.- 2002.- V. 287.- P 195-202. https://doi.org/10.1001/jama.287.2.195
  41. Karnaukh N. G. Zabolevayemost' ifunktsional'noyesostoyaniyeserdechno-sosudistoysistemy u metallurgov / Karnauk N. G, Pavlenko M. Ye. // Sb. Gigiyenatruda.- 1978.- Vyp. 14.- S. 28-31.
  42. Gorban' L. N. Vliyaniyeusloviytrudanasostoyaniyezdorov'ya i zabolevayemost' rabotayushchikh v svarochnomproizvodstve / Gorban' L. N., KrasnyukYe. P., Faktorov I. Ye. // Sb. Gigiyenatruda.- 1963.- Vyp. 19.- S. 40-49.
  43. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis. A 3-year follow-up study / [Sander D., Kukla C., Klingelhofer J. et al.] // Circulation.-2000.- V. 102.- P 1536-1541. https://doi.org/10.1161/01.CIR.102.13.1536
  44. Respiratory disease and cardiovascular morbidity / Koskela R.- S., Mutanen P., Sorsa J.- A., Klockars M. // Occupational and Environmental Medicine.- 2005.- V. 62.- P 650-655. https://doi.org/10.1136/oem.2004.017111
  45. Villeneuve P. J. Coronary heart disease mortality among Newfoundland fluorspar miners. Department of Preventive Medicine and Biostatistics, University of Toronto, Laboratory Centre for Disease Control, Health Canada / Villeneuve P J., Morrison H. I. // Scandinavian journal of work, environment & health ISSN 0355-3140.1997.- V. 23.- No 3.- P 221-226 (29 ref.). https://doi.org/10.5271/sjweh.202
  46. Vascular-Protective Effects of High-Density Lipoprotein Include the Downregulation of the Angiotensin II Type 1 Receptor/ [Sophie Van Linthout, Frank Spillmann, Mario Lorenz et al.] // Hypertension.- 2009.- V. 53.- P. 587-589. https://doi.org/10.1161/HYPERTENSIONAHA.108.118919
  47. Cardiac Overexpression of Angiotensin Converting Enzyme 2 Protects the Heart From Ischemia-Induced Pathophysiology / [Shant Der Sarkissian, Justin L. Grobe, Lihui Yuan et al.] // Hypertension.- 2008.- V. 51.- P 712. https://doi.org/10.1161/HYPERTENSIONAHA.107.100693
  48. Mohan K. Raizada. Potential of Gene Therapy Strategy for the Treatment of Hypertension / Mohan K. Raizada, Shant Der Sarkissian // Hypertension.-2006.- V. 47.- P. 6. https://doi.org/10.1161/01.HYP.0000196685.91424.01
  49. Der Sarkissian S., Huentelman M.J., Stewart J., Katovich M.J., Raizada M.K. ACE2: A novel therapeutic target for cardiovascular diseases. ProgBiophysMolBiol. 2005:Jul 8.
  50. Pachori A.S., Huentelman M.J., Francis S.C., Gelband C.H., Katovich M.J., Raizada M.K. The future of hypertension therapy: sense, antisense, or nonsense? Hypertension.- 2001.- V. 37.- P. 357-364. https://doi.org/10.1161/01.HYP.37.2.357
  51. Blakita I. V. Biokhimicheskiyeizmeneniya v miokardeprikhronicheskomvozdeystviietilmerkurkhlorida i khlorofosa / I. V. Blakita // Gig. tr. i prof. zd-ya.- 1986.- No 5.- S. 46-47.
  52. Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats / [Zhao C., Wang P., Xiao X. et al.] // Hypertension.- 2003.- V. 42.- P. 1026-1033. https://doi.org/10.1161/01.HYP.0000097603.55404.35
  53. Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen / [Tomita N., Morishita R., Higaki J. et al.] // Hypertension.- 1995.- V. 26.- P. 131-136. https://doi.org/10.1161/01.HYP.26.1.131
  54. Galli S. M. Angiotensin II AT(1A) receptor antisense lowers blood pressure in acute 2-kidney, 1-clip hypertension / Galli S. M., Phillips M. I. // Hypertension.- V. 38,-P. 674-678. https://doi.org/10.1161/hy09t1.095207
  55. Chronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotensin type 1 receptor antisense / Lyer S. N., Lu D., Katovich M. J., Raizada M.K // Proc Natl AcadSci U S A.- 1996.- V. 93.- P. 9960 -9965. https://doi.org/10.1073/pnas.93.18.9960
  56. Blood pressure-independent attenuation of cardiac hypertrophy by AT(1)R-AS gene therapy / [Pachori A. S., Numan M. T., Ferrario C.M. et al.] // Hypertension.- V. 39.- P. 969-975. https://doi.org/10.1161/01.HYP.0000017827.63253.16
  57. The future of hypertension therapy: sense, antisense, or nonsense? / [Pachori A. S., Huentelman M. J., Francis S.C. et al.] // Hypertension.-2001.- V. 37.- P. 357-364. https://doi.org/10.1161/01.HYP.37.2.357
  58. Sustained inhibition of angiotensin I-converting enzyme (ACE) expression and long-term antihypertensive action by virally mediated delivery of ACE antisense cDNA / [Wang H., Katovich M. J., Gelband C. H. et al.] // Circ Res.- 1999.- V. 85.- P. 614-622. https://doi.org/10.1161/01.RES.85.7.614
  59. Akhmeteli M. A. Epidemiologicheskiyeissledovaniyaserdechno-sosudistykhzabolevaniy i ikhprofilaktika / Akhmeteli M. A. // Sov. zdravookh.- 1982.- No 5.- S. 20-23.
  60. Attenuation of hypertension and heart hypertrophy by adeno-associated virus delivering angiotensinogen antisense / Kimura B., Mohuczy D., Tang X., Phillips M. I. // Hypertension.- 2001.- V. 37.- P. 376-380. https://doi.org/10.1161/01.HYP.37.2.376
  61. Antisense inhibition of beta(1)-adrenergic receptor mRNA in a single dose produces a profound and prolonged reduction in high blood pressure in spontaneously hypertensive rats /Zhang Y. C., Bui J. D., Shen L., Phillips M. I // Circulation.-2000.- V. 101.- P. 682-688. https://doi.org/10.1161/01.CIR.101.6.682
  62. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense / [Kagiyama S., Eguchi S., Frank G.D. et al.] // Circulation.- 2002.- V. 106.- P 909-912. https://doi.org/10.1161/01.CIR.0000030181.63741.56
  63. Antisense to epidermal growth factor receptor prevents the development of left ventricular hypertrophy / Kagiyama S., Qian K., Kagiyama T., Phillips M. I. // Hypertension.- 2003.- V. 41.- P 824-829. https://doi.org/10.1161/01.HYP.0000047104.42047.9B
  64. Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats / Dobrzynski E., Wang C., Chao J., Chao L. // Hypertension.- 2000.- V. 36.- P 995-1001. https://doi.org/10.1161/01.HYP.36.6.995
  65. Lin K. F. Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats / Lin K. F., Chao J., Chao L. // Hypertension.- 1995.- V. 26.- P 847-853. https://doi.org/10.1161/01.HYP.26.6.847
  66. Wang C. Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats / Wang C., Chao L., Chao J. // J Clin Invest.- 1995.- V. 95.- P 1710-1716. https://doi.org/10.1172/JCI117847
  67. Human tissue kallikrein attenuates hypertension and secretes into circulation and urine after intramuscular gene delivery in hypertensive rats / [Zhang J. J., Wang C., Lin K. F. et al.] // ClinExpHypertens.- 1999.- V. 21.- P 1145-1160. https://doi.org/10.3109/10641969909052194
  68. Babayan E. A. Gigiyenicheskayareglamentatsiyakhimicheskikhveshchestv v okruzhayushcheysrede s uchetomikhdeystviyana SSS / E. A. Babayan // V kn.: Mat. nauchn. konf. porezul'tatam NIR mezhvedomstvenn. Programmy MZ i AN ArmSSRYerevan, 1985.- S. 14. 69.
  69. Babayan E. A. Nekotoryyemetodicheskiyevoprosygigiyenicheskogonormirovaniyakardiotoksicheskikhveshchestv v vozdukherabocheyzony / E. A. Babayan // V kn.: Probl. okhranyzdorov'yanaseleniya i zashchityokruzhayushcheysredyotkhimicheskikhvrednykhfaktorov: Tez.dokl. I Vsesoyuzn. s"yezdatoksikologov.- Rostov-na-Donu, 1986.- S. 48-49.
  70. Prevention of cardiac hypertrophy by angiotensin II type-2 receptor gene transfer / [Metcalfe B. L., Huentelman M. J., Parilak L. D. et al.] // Hypertension.- 2004.- V. 43.- P. 1233-1238. https://doi.org/10.1161/01.HYP.0000127563.14064.fd
  71. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril- insensitive carboxypeptidase / [Tipnis S. R., Hooper N. M., Hyde R. et al.] // J Biol Chem.- 2000.- V. 275.- P. 33238-33243. https://doi.org/10.1074/jbc.M002615200
  72. Turner A. J. The angiotensin-converting enzyme gene family: genomics and pharmacology / A. J. Turner, N. M. Hooper // Trends Pharmacol Sci.- 2002.- V. 23.- P. 177-183. https://doi.org/10.1016/S0165-6147(00)01994-5
  73. Angiotensin-converting enzyme 2 is an essential regulator of heart function / [Crackower M. A., Sarao R., Oudit G. Y. et al.] // Nature.- 2002.- V. 417.- P. 822-828. https://doi.org/10.1038/nature00786
  74. Angiotensin-(1-7) is a modulator of the human renin-angiotensin system / [Roks A. J., van Geel P. P, Pinto Y. M. et al.] // Hypertension.- 1999.- V. 34.- P. 296-301. https://doi.org/10.1161/01.HYP.34.2.296
  75. Angiotensin-(1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man / [Ueda S., Masumori-Maemoto S., Ashino K. et al.] // Hypertension.- 2000.- V. 35.- P. 998-1001. https://doi.org/10.1161/01.HYP.35.4.998
  76. Protection from angiotensin Il-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 / [Huentelman M. J., Grobe J. L., Vazquez J. et al.] // Exp Physiol.- 2005.- V. 90.- P. 783-790. https://doi.org/10.1113/expphysiol.2005.031096
  77. Cloning and characterization of a secreted form of angiotensin-converting enzyme 2 / Huentelman M. J., Zubcevic J., Katovich M. J., Raizada M. K. // RegulPept.- 2004.- V. 122.- P 61-67. https://doi.org/10.1016/j.regpep.2004.05.003
  78. Protection from ischemic heart injury by a vigilant heme oxygenase-1 plasmid system / [Tang Y. L., Tang Y., Zhang Y. C. et al.] // Hypertension.-2004.- V. 43.- P 746-751. https://doi.org/10.1161/01.HYP.0000120152.27263.87